---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-323057"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2021-11-08T23:59:59+00:00"
generated_at: "2026-06-28T11:43:19.667309+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytek Q3 revenue $34.4M (+37% YoY); net income $1.6M down from $6.5M

## Summary
- Total revenue $34.4M, up 37% YoY; gross margin 62% (non-GAAP 64%).
- Net income $1.6M, down from $6.5M YoY; non-GAAP net income $4.1M vs $6.7M.
- Operating expenses $18.3M, up 106% YoY due to public company costs and R&D investment.
- Cash $377M; installed base expanded to 970 instruments with 115 placements in Q3.
- Announced acquisition of Tonbo Biosciences' cell analysis business to enhance reagent portfolio.

## SEC filing metadata
- accession: 0001193125-21-323057
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2021-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312521323057/0001193125-21-323057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312521323057/d257430d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-323057
- JSON: https://secwatch.observer/filing/0001193125-21-323057.json
- Plain text: https://secwatch.observer/filing/0001193125-21-323057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.